VRXA · Veraxa Biotech AG
United States · RS rating 8 · As of 2026-11-03
| Price | 0.99 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 8 / 31 / 11 / 5 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 7 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +96.0% |
| Market cap (USD) | $2.7B |